People · Operator
Named in public records as an officer, director or promoter · active 2024–2024 · Pharmaceuticals, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| TORL Biotherapeutics LLC | — | Pharmaceuticals | Series D+ | $158.3M | $1.8B | 2024 |
| 1200 Pharma LLC | — | Pharma | Series A | $14.1M | $13.2M | 2024 |
Dennis Slamon at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Dennis Slamon on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Licata | 2 | 4 |
| Mark Attanasio | 2 | 3 |
| David Chang | 1 | 6 |
| Mark Alles | 1 | 3 |
| Neil ` O'Brien | 1 | 3 |
| Amit Sinha | 1 | 2 |
| LEE SAILOR | 1 | 2 |
| Lynn Seely | 1 | 1 |
| Brian Stoltz | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.